Compare SELF & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SELF | XLO |
|---|---|---|
| Founded | 1983 | 2016 |
| Country | United States | United States |
| Employees | 36 | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.1M | 56.9M |
| IPO Year | 1997 | 2021 |
| Metric | SELF | XLO |
|---|---|---|
| Price | $5.10 | $9.11 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 1 |
| Target Price | $6.00 | ★ $28.00 |
| AVG Volume (30 Days) | 17.2K | ★ 35.6K |
| Earning Date | 05-08-2026 | 05-14-2026 |
| Dividend Yield | ★ 5.25% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | $12,705,245.00 | ★ $43,766,000.00 |
| Revenue This Year | $3.04 | N/A |
| Revenue Next Year | $3.47 | $168.77 |
| P/E Ratio | $127.25 | ★ N/A |
| Revenue Growth | 1.40 | ★ 589.88 |
| 52 Week Low | $4.73 | $0.46 |
| 52 Week High | $5.63 | $9.89 |
| Indicator | SELF | XLO |
|---|---|---|
| Relative Strength Index (RSI) | 45.63 | 52.87 |
| Support Level | $5.01 | $8.31 |
| Resistance Level | $5.09 | $9.89 |
| Average True Range (ATR) | 0.08 | 0.39 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 36.36 | 69.35 |
Global Self Storage Inc is a self-administered and self-managed REIT that owns, operates, manages, acquires, develops, and redevelops self-storage properties. The company's self-storage properties are designed to offer affordable, easily accessible, and secure storage space for residential and commercial customers. It has one segment of Rental operations. Through its wholly-owned subsidiaries, the company owns and/or manages close to thirteen self-storage properties in Connecticut, Illinois, Indiana, New York, Ohio, Pennsylvania, South Carolina, and Oklahoma.
Xilio Therapeutics Inc is a clinical-stage biotechnology company focused on discovering and developing masked immuno-oncology (I-O) therapies to improve outcomes for people living with cancer. Leveraging its clinically validated masking technology and capabilities, the company develops I-O therapies designed to selectively activate within the tumor microenvironment to achieve durable efficacy without the severe side effects associated with systemically active I-O agents. Its integrated biology and protein engineering approach enables the design and development of potent masked biologics that are activated by tumor-specific proteases.